OpGen Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de OpGen.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	20.6%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

OpGen to raise $3.38M in direct stock offering

Sep 30

OpGen's subsidiary signs R&D agreement with FIND

Sep 20

Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement

Aug 31

OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia

Jan 05

OpGen launches $10M private placement

Nov 24

OpGen EPS misses by $0.04, beats on revenue

Nov 11

OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform

Oct 28

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como OpGen no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:OPGN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2023	3	-26	-18	-17	N/A
6/30/2023	3	-36	-20	-18	N/A
3/31/2023	3	-36	-21	-20	N/A
12/31/2022	3	-37	-21	-20	N/A
9/30/2022	3	-41	-21	-20	N/A
6/30/2022	4	-33	-21	-21	N/A
3/31/2022	4	-34	-23	-22	N/A
12/31/2021	4	-42	-23	-21	N/A
9/30/2021	4	-35	-27	-25	N/A
6/30/2021	4	-37	-29	-27	N/A
3/31/2021	4	-37	-27	-26	N/A
12/31/2020	4	-26	-24	-23	N/A
9/30/2020	4	-22	-20	-20	N/A
6/30/2020	3	-17	-15	-15	N/A
3/31/2020	3	-13	-11	-11	N/A
12/31/2019	3	-12	-12	-12	N/A
9/30/2019	3	-14	-11	-11	N/A
6/30/2019	3	-13	-12	-11	N/A
3/31/2019	3	-14	-12	-12	N/A
12/31/2018	3	-13	-11	-11	N/A
9/30/2018	3	-13	-12	-11	N/A
6/30/2018	3	-13	-12	-12	N/A
3/31/2018	3	-13	-12	-12	N/A
12/31/2017	3	-15	-15	-14	N/A
9/30/2017	3	-17	-16	-16	N/A
6/30/2017	3	-19	N/A	-16	N/A
3/31/2017	4	-20	N/A	-18	N/A
12/31/2016	4	-19	N/A	-17	N/A
9/30/2016	4	-19	N/A	-16	N/A
6/30/2016	5	-19	N/A	-19	N/A
3/31/2016	4	-19	N/A	-16	N/A
12/31/2015	3	-18	N/A	-14	N/A
9/30/2015	3	-14	N/A	-13	N/A
6/30/2015	3	-12	N/A	-7	N/A
3/31/2015	4	-8	N/A	-6	N/A
12/31/2014	4	-6	N/A	-5	N/A
9/30/2014	4	-9	N/A	-5	N/A
12/31/2013	2	-16	N/A	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de OPGN es superior a la tasa de ahorro (2.3%).

Beneficios frente mercado: Datos insuficientes para determinar si se prevé que los beneficios de OPGN crezcan más deprisa que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de OPGN crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de OPGN crezcan más rápido que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de OPGN crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de OPGN se prevé elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

OpGen Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022

OpGen, Inc. Provides Revenue Guidance for Fiscal Year 2022

OpGen, Inc. Provides Earnings Guidance for the Year 2022

OpGen, Inc. Provides Revenue Guidance for the Year 2022

Recent updates

OpGen, Inc. announced delayed annual 10-K filing

OpGen, Inc. announced delayed annual 10-K filing

Opgen, Inc. Announces Executive Changes

New major risk - Share price stability

New major risk - Revenue and earnings growth

OpGen Submits A Request for A Hearing Before the Panel, Which Request Stayed Any Suspension or Delisting Action by Nasdaq At Least Until the Hearing Process Concludes and Any Extension Granted by the Panel Expires

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

OpGen, Inc. announced that it expects to receive $1 million in funding

OpGen, Inc. announced that it expects to receive $1 million in funding

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

OpGen, Inc. to Report Q2, 2023 Results on Aug 10, 2023

OpGen Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement

First quarter 2023 earnings released: US$1.25 loss per share (vs US$2.93 loss in 1Q 2022)

OpGen, Inc. to Report Q1, 2023 Results on May 15, 2023

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

OpGen, Inc Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Reports Goodwill Impairment Charge for the Third Quarter Ended September 30, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.38 million.

OpGen, Inc. Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel

OpGen to raise $3.38M in direct stock offering

OpGen's subsidiary signs R&D agreement with FIND

Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement

Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement

Opgen, Inc. Launches Ares Sequencing Services in the U.S. from Its Rockville, Maryland Laboratory

OpGen launches sequencing services for infectious diseases in US

OpGen, Inc. Provides Revenue Guidance for Fiscal Year 2022

OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-line

OpGen, Inc. to Report Q2, 2022 Results on Aug 11, 2022

OpGen reports preliminary revenue estimate for Q2 2022

OpGen, Inc. Announces Publication of Results of Unyvero Hospitalized Pneumonia (Hpn) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized Covid-19 Patients

OpGen, Inc. Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia Panel in the Lancet Respiratory Medicine

OpGen, Inc. Provides Earnings Guidance for the Year 2022

OpGen, Inc., Annual General Meeting, Jun 09, 2022

OpGen, Inc. Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Provides Revenue Guidance for the Year 2022

OpGen, Inc. Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

OpGen gains on insider buying

OpGen, Inc. Submits Updated 510(k) Summary to FDA For Acuitas AMR Gene Panel for Isolates

OpGen submits 510(k) summary to FDA for Acuitas AMR Gene Panel for Isolates

OpGen, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Evan Jones, Director of Opgen, Inc. Will Not Stand for Re-Election at the 2021 Annual Meeting of Stockholders

OpGen, Inc., Annual General Meeting, Jun 09, 2021

OpGen reports prelim Q4 & FY20 revenue

OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia

OpGen, Inc. Announces Results from 1,400 Patient Sample Multicenter Study Published: Unyvero LRT BAL Panel Provides Accurate Detection in Bronchoalveolar Lavage Fluid, Allowing Enhanced Diagnosis of Lower Respiratory Tract Infections

OpGen, Inc. announced that it expects to receive $10 million in funding

OpGen launches $10M private placement

OpGen EPS misses by $0.04, beats on revenue

OpGen, Inc. to Report Q3, 2020 Results on Nov 11, 2020

OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform

OpGen, Inc. Demonstrates the Clinical Utility of Unyvero LRT Panel and Its Potential Impact on Antibiotic Use in Hospitalized Patients with Suspected Pneumonia

OpGen, Inc. Announces Successful Completion of Study Collaboration with Karolinska Institutet on Bacterial Co-Infections in Covid-19 Pneumonia Patients and Presents Data on Unyvero Hpn Panel At Eccvid 2020

OpGen, Inc. May File for Bankruptcy

OpGen, Inc. to Report Q2, 2020 Results on Aug 12, 2020

OpGen, Inc. (NasdaqCM:OPGN) completed the acquisition of Curetis AG (“Curetis”) from Curetis N.V. (ENXTAM:CURE).

New 90-day high - US$2.44

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento